THIRD HARMONIC BIO INC (THRD)
US88427A1079 - Common Stock
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling...
What's going on in today's session
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Interesting THRD Call Options For May 2025
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on...
Third Harmonic Bio to Participate in Upcoming Investor Conferences
Third Harmonic Bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing...
THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q2 2024
THRD stock results show that Third Harmonic Bio beat analyst estimates for earnings per share the second quarter of 2024.
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position...
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing...
THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q1 2024
THRD stock results show that Third Harmonic Bio beat analyst estimates for earnings per share the first quarter of 2024.
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results...
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...
THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q4 2023
THRD stock results show that Third Harmonic Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The...
Third Harmonic Bio is Now Oversold (THRD)
Third Harmonic appoints Christopher Murphy as CFO (NASDAQ:THRD)
Third Harmonic Bio appoints Christopher Murphy as Chief Financial and Business Officer, signaling progress towards their Phase 1 study on THB335.
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The...
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with...
Third Harmonic Bio says CFO Robert Ho to leave co (NASDAQ:THRD)
THRD announces CFO's departure and CSO's transition in executive positions.
Third Harmonic Bio Announces Leadership Changes
Third Harmonic Bio Announces Leadership Changes
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...
Third Harmonic Bio files for a mixed shelf offering of $400M (NASDAQ:THRD)
THRD filed a mixed shelf prospectus to potentially raise $400M.
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...